How cancer hides from immune cells, and the molecular trick it uses
Cancer cells have a way of making themselves invisible to the immune system’s hunters. New research reveals how tumors recycle two key surface proteins through their internal transport network, causing T cells to lose their grip.
When a T cell attacks a cancer cell, it does not do so at random. A precise molecular contact point is required: the immune synapse, a temporary but organized connection between the T cell and the cancer cell through which signals are exchanged that activate the T cell to kill. But tumors are evolutionarily resourceful, they have developed ways to disrupt that synapse before the killing can begin.
A study published in eLife describes how cancer cells use a specific protein transport system, clathrin-independent endocytosis mediated by a protein called EndoA3, to remove two molecules from the cell surface that are critical for immune synapse formation: ICAM-1 and ALCAM. Endocytosis is the process by which a cell takes molecules from its outer membrane and moves them inside. In this case, those two proteins are not simply degraded; they are transported back to an internal depot, the trans-Golgi network, from where they can be strategically redistributed.
Recycling as a survival strategy
What makes this mechanism notable is the logistical sophistication. The cancer cell does not permanently delete ICAM-1 and ALCAM, it actively manages their presence on the surface. By temporarily withdrawing them when a T cell approaches, the tumor reduces the likelihood of effective recognition and attack. This is not passive invisibility but active immunological sabotage.
The finding is relevant to understanding immunotherapy, treatments that enlist the patient’s own immune system to fight cancer. Checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 have transformed oncology over the past decade, but a substantial proportion of patients do not respond. Part of that resistance may be explained by mechanisms like the one described here: the tumor disrupts the physical interaction with the T cell before inhibitory signaling even comes into play.
A new therapeutic target?
If EndoA3 is the key protein driving this transport system, it becomes a potential therapeutic target. Blocking EndoA3 could allow ICAM-1 and ALCAM to remain on the cancer cell surface longer, enabling better immune synapse formation and more effective T cell killing. Whether that works in practice without unwanted side effects is a question for preclinical and clinical studies, which have not yet been done.
The research reflects a broader pattern in cancer immunology: the more precisely we map the molecular communication between the immune system and tumors, the more potential intervention points we identify. But also: the more complex the puzzle turns out to be.